A sensitivity scale for targeting T cells with chimeric antigen receptors (CARs) and bispecific T-cell Engagers (BiTEs)
出版年份 2012 全文链接
标题
A sensitivity scale for targeting T cells with chimeric antigen receptors (CARs) and bispecific T-cell Engagers (BiTEs)
作者
关键词
-
出版物
OncoImmunology
Volume 1, Issue 6, Pages 863-873
出版商
Informa UK Limited
发表日期
2012-06-19
DOI
10.4161/onci.20592
参考文献
相关参考文献
注意:仅列出部分参考文献,下载原文获取全部文献信息。- Antigen Sensitivity of CD22-Specific Chimeric TCR Is Modulated by Target Epitope Distance from the Cell Membrane
- (2014) S. E. James et al. JOURNAL OF IMMUNOLOGY
- CAR T cells transform to trucks: chimeric antigen receptor–redirected T cells engineered to deliver inducible IL-12 modulate the tumour stroma to combat cancer
- (2012) Markus Chmielewski et al. CANCER IMMUNOLOGY IMMUNOTHERAPY
- Chimeric antigen receptors for T cell immunotherapy: current understanding and future directions
- (2012) Kevin J. Curran et al. JOURNAL OF GENE MEDICINE
- Targeting mutations predictably
- (2011) H. Schreiber et al. BLOOD
- Immunomodulatory therapy of cancer with T cell-engaging BiTE antibody blinatumomab
- (2011) Dirk Nagorsen et al. EXPERIMENTAL CELL RESEARCH
- Targeted Therapy With the T-Cell–Engaging Antibody Blinatumomab of Chemotherapy-Refractory Minimal Residual Disease in B-Lineage Acute Lymphoblastic Leukemia Patients Results in High Response Rate and Prolonged Leukemia-Free Survival
- (2011) Max S. Topp et al. JOURNAL OF CLINICAL ONCOLOGY
- The immunoregulatory mechanisms of carcinoma for its survival and development
- (2011) Caigan Du et al. JOURNAL OF EXPERIMENTAL & CLINICAL CANCER RESEARCH
- Chimeric Antigen Receptor–Modified T Cells in Chronic Lymphoid Leukemia
- (2011) David L. Porter et al. NEW ENGLAND JOURNAL OF MEDICINE
- T Cells with Chimeric Antigen Receptors Have Potent Antitumor Effects and Can Establish Memory in Patients with Advanced Leukemia
- (2011) M. Kalos et al. Science Translational Medicine
- Building Better Chimeric Antigen Receptors for Adoptive T Cell Therapy
- (2010) John S. Bridgeman et al. CURRENT GENE THERAPY
- Features of responding T cells in cancer and chronic infection
- (2010) Peter S Kim et al. CURRENT OPINION IN IMMUNOLOGY
- Mathematical Modeling of Chimeric TCR Triggering Predicts the Magnitude of Target Lysis and Its Impairment by TCR Downmodulation
- (2010) S. E. James et al. JOURNAL OF IMMUNOLOGY
- Case Report of a Serious Adverse Event Following the Administration of T Cells Transduced With a Chimeric Antigen Receptor Recognizing ERBB2
- (2010) Richard A Morgan et al. MOLECULAR THERAPY
- Antibody recognition of a unique tumor-specific glycopeptide antigen
- (2010) C. L. Brooks et al. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
- Bispecific T-Cell Engaging Antibodies for Cancer Therapy
- (2009) P. A. Baeuerle et al. CANCER RESEARCH
- T Cell Receptor Gene Therapy for Cancer
- (2009) Thomas M. Schmitt et al. HUMAN GENE THERAPY
- The Impact of TCR-Binding Properties and Antigen Presentation Format on T Cell Responsiveness
- (2009) A. S. Chervin et al. JOURNAL OF IMMUNOLOGY
- A Herceptin-Based Chimeric Antigen Receptor with Modified Signaling Domains Leads to Enhanced Survival of Transduced T Lymphocytes and Antitumor Activity
- (2009) Y. Zhao et al. JOURNAL OF IMMUNOLOGY
- Evolving novel anti-HER2 strategies
- (2009) Kellie L Jones et al. LANCET ONCOLOGY
- HER2-targeted therapy in breast cancer. Monoclonal antibodies and tyrosine kinase inhibitors
- (2008) Dorte Lisbet Nielsen et al. CANCER TREATMENT REVIEWS
- Engineering higher affinity T cell receptors using a T cell display system
- (2008) Adam S. Chervin et al. JOURNAL OF IMMUNOLOGICAL METHODS
- Tumor Regression in Cancer Patients by Very Low Doses of a T Cell-Engaging Antibody
- (2008) R. Bargou et al. SCIENCE
- Tumor-specific immune responses
- (2008) Hans Schreiber SEMINARS IN IMMUNOLOGY
Find Funding. Review Successful Grants.
Explore over 25,000 new funding opportunities and over 6,000,000 successful grants.
ExploreAsk a Question. Answer a Question.
Quickly pose questions to the entire community. Debate answers and get clarity on the most important issues facing researchers.
Get Started